Jaranit Kaewkungwal
A5062923881- HIV Research and Treatment
- Malaria Research and Control
- Mosquito-borne diseases and control
- Immune Cell Function and Interaction
- Tuberculosis Research and Epidemiology
- HIV/AIDS Research and Interventions
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis C virus research
- Hepatitis B Virus Studies
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- HIV, Drug Use, Sexual Risk
- Pneumonia and Respiratory Infections
- Ethics in Clinical Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Mobile Health and mHealth Applications
- Global Maternal and Child Health
- Viral Infections and Vectors
- Herpesvirus Infections and Treatments
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Data-Driven Disease Surveillance
- ICT in Developing Communities
Mahidol University
2015-2024
Mahidol Oxford Tropical Medicine Research Unit
2015-2024
Ministry of Public Health
1999-2022
Armed Forces Research Institute of Medical Science
2014-2021
Department of Disease Control
2017
Universitas Islam Malang
2017
Royal Thai Army
2014-2015
Hospital for Tropical Diseases
2015
Biophics
2011-2014
Center for Excellence in Education
2014
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.In community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections recombinant canarypox vector (ALVAC-HIV [vCP1521]) plus two booster glycoprotein 120 subunit (AIDSVAX B/E). placebo were administered 16,402 healthy men women between ages 18 30 years in Rayong Chon Buri provinces Thailand....
In the RV144 trial, estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed case–control analysis to identify antibody and cellular immune correlates infection risk.
A V1-V2 IgG3 response to HIV correlates with a decreased risk of HIV-1 infection and is one vaccine-induced humoral that higher in clinical trial showing vaccine efficacy compared nonefficacy.
Analysis of correlates risk infection in the RV144 HIV-1 vaccine efficacy trial demonstrated that plasma IgG against envelope (Env) variable region 1 and 2 inversely correlated with risk, whereas Env-specific IgA responses directly risk. In secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was another inverse correlate but only presence low antibodies. Thus, we investigated hypothesis could attenuate protective effect through competition for same Env binding sites. We...
The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only AIDSVAX B/E) was not protective. Because protection within observed the absence neutralizing antibody activity or cytotoxic T cell responses, we speculated that specificity qualitative differences Fc-effector profiles nonneutralizing antibodies may have accounted for between two trials. We...
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. secondary immune correlate analysis demonstrated that the combination low plasma anti-HIV-1 Env IgA antibodies and high levels antibody-dependent cellular cytotoxicity (ADCC) inversely with infection risk. One hypothesis is observed protection in partially due to ADCC-mediating antibodies. We found majority (73 90%) a representative group vaccinees displayed ADCC activity, usually (96.2%) blocked by...
A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in community-based population Thailand (RV144 trial). No was observed Thai injection drug users who received AIDSVAX B/E alone (Vax003 We compared the neutralizing antibody response these 2 trials.
In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of envelope glycoprotein gp120 were an inverse correlate risk infection. To determine if V1V2-specific Abs cross-react with V1V2 from different subtypes, nature antigen used asses cross-reactivity influenced infection risk, identify immune assays for upcoming trials, new V1V2-scaffold antigens designed tested. Protein scaffold carrying subtypes A, B, C, D or CRF01_AE assayed in...
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope glycoproteins have potential mediate antiviral effector functions that could be beneficial vaccine-induced protection. Here, plasma IgG responses were assessed in three gp120 vaccine efficacy trials (RV144, Vax003, Vax004) HIV-1-infected individuals by using arrays of overlapping peptides spanning the entire consensus gp160 all major genetic subtypes circulating recombinant forms (CRFs) virus. In RV144, where...
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against gp120 envelope (Env). Peptide microarray analysis six subtypes group M consensus that vaccination induced to the second variable (V2) loop of multiple subtypes. We further evaluated V2 by ELISA surface plasmon resonance...
ABSTRACT The RV144 ALVAC/AIDSVax HIV-1 vaccine clinical trial showed an estimated efficacy of 31.2%. Viral genetic analysis identified a vaccine-induced site immune pressure in the envelope (Env) variable region 2 (V2) focused on residue 169, which is included epitope recognized by vaccinee-derived V2 monoclonal antibodies. induced antibody-dependent cellular cytotoxicity (ADCC) against Env and constant 1 (C1) regions. In presence low IgA antibody levels, plasma levels ADCC activity...
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of that most likely protective, they not induced current vaccine candidates. In contrast, do neutralize primary strains in TZM-bl infection assay readily by candidates and have also been implicated as secondary correlates decreased risk RV144 efficacy trial. Here, we studied capacity anti-Env...
Malaria still remains a public health problem in some districts of Bhutan despite marked reduction cases last few years. To strengthen the country's prevention and control measures, this study was carried out to develop forecasting prediction models malaria incidence endemic using time series ARIMAX.This retrospectively monthly reported from centres Vector-borne Disease Control Programme (VDCP) meteorological data Meteorological Unit, Department Energy, Ministry Economic Affairs. Time...
The Thai HIV phase III prime/boost vaccine trial (RV144) using ALVAC-HIV (vCP1521) and AIDSVAX B/E was, to our knowledge, the first demonstrate acquisition efficacy. Vaccine-induced, cell-mediated immune responses were assessed. T cell epitope mapping studies IFN-γ ELISPOT was performed on PBMCs from HIV-1-uninfected (n = 61) placebo 10) recipients HIV-1 Env peptides. Positive measured in 25 (41%) vaccinees predominantly CD4(+) cell-mediated. Responses targeted within region, with 15 of...
The phase III RV144 HIV-1 vaccine trial estimated efficacy (VE) to be 31.2%. This demonstrated that the presence of HIV-1-specific IgG-binding Abs envelope (Env) V1V2 inversely correlated with infection risk, while Env-specific plasma IgA directly risk infection. Moreover, Ab-dependent cellular cytotoxicity responses in recipients low IgA; therefore, we hypothesized vaccine-induced Fc receptor-mediated (FcR-mediated) Ab function is indicative protection. We sequenced exons and surrounding...
To assess the application of cell phone integrating into healthcare system to improve antenatal care (ANC) and expanded programme on immunization (EPI) services for under-served population in border area. A module combining web-based mobile technology was developed generate ANC/EPI visit schedule dates which personnel can cross-check, identify update mother's ANC child's EPI status at facility or household location when performing home visit; with additional feature sending appointment...
ABSTRACT An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to gp120 V1/V2 region correlated inversely with infection risk. The protein immunogens (A244-rp120 and MN-rgp120) were modified by an N-terminal 11-amino-acid deletion (Δ11) addition a herpes simplex virus (HSV) gD protein-derived tag (gD). We investigated effects these modifications on expression, antigenicity, immunogenicity comparing unmodified A244 both Δ11 only. Analysis gp120, or...
The Thai-Myanmar border is a remaining hotspot for malaria transmission. Malaria transmission in this region continues year-round, with major peak season July-August, and minor October-November. elimination requires better knowledge of the mosquito community structure, dynamics vectorial status to support effective vector control. Adult Anopheles mosquitoes were collected using CDC light traps cow bait 7 villages along January 2011 - March 2013. Mosquitoes determined species by morphological...
To determine the incidence of HIV-1 infection, temporal trends in incidence, and risk factors for seroconversion a cohort female commercial sex workers (CSW) upper northern Thailand, region Thailand with highest rates infection.CSW were enrolled from 1991 through 1994 evaluated prospectively interviews, physical examination, testing sexually transmitted diseases (STD), serologic infection.The first year follow-up was 20.3 per 100 person-years among 126 brothel-based CSW 0.7 159 other who...
To measure trends in the incidence of HIV-1 infection among drug users treatment at Thailand's largest detoxification unit.A retrospective cohort was established using computed, existing test results 26,396 inpatients and outpatients admitted for 47,907 courses from August 1987 to 1992.Matching patient record numbers showed that 10,050 (38.1%) patients had been two or more times during period. From these, we selected a 7807 initially HIV-negative patients. Subsequent seroconversions them...
Abstract Background Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after initial attack. For 50 years, primaquine been used as hypnozoitocide to radically cure P. infection, but major concerns remain regarding side-effects of drug and adherence 14-day regimen. This study examined effectiveness using directly-observed therapy (DOT) method for radical treatment malaria prevent reappearance parasite within 90-day follow-up period. Other...